Loading...
•
Jun 30, 2022
ORIC Pharmaceuticals Q2 2022 Earnings Report
Reported financial results and operational updates for the second quarter of 2022.
Key Takeaways
ORIC Pharmaceuticals reported its Q2 2022 financial results, highlighting a strong cash position of $237.8 million expected to fund operations into 2H 2024, and progress in its clinical programs with initial data expected in 1H 2023.
Three ongoing single agent Phase 1 programs (ORIC-533, ORIC-114, and ORIC-944) are expected to report initial data in 1H 2023.
Preclinical data from ORIC-533 and ORIC-114 programs were presented at AACR in April 2022.
Cash and investments totaled $237.8 million as of June 30, 2022.
The company expects its cash position to fund the current operating plan into the second half of 2024.
ORIC Pharmaceuticals
ORIC Pharmaceuticals
Forward Guidance
ORIC anticipates initial Phase 1b data from ORIC-533, ORIC-114, and ORIC-944 in 1H 2023, with cash and investments expected to fund operations into 2H 2024.
Positive Outlook
- Initial Phase 1b data from ORIC-533 expected in 1H 2023.
- Initial Phase 1b data from ORIC-114 expected in 1H 2023.
- Initial Phase 1b data from ORIC-944 expected in 1H 2023.
- Cash and investments of $237.8 million expected to fund operations into 2H 2024.